Zafgen Inc. (ZFGN) Stock Price Down 3.1%
Zafgen Inc. (NASDAQ:ZFGN) was down 3.1% during mid-day trading on Friday . The stock traded as low as $3.09 and last traded at $3.10, with a volume of 142,855 shares. The stock had previously closed at $3.20.
Several equities research analysts have issued reports on ZFGN shares. FBR & Co reaffirmed a “buy” rating on shares of Zafgen in a research note on Monday, June 13th. Zacks Investment Research raised shares of Zafgen from a “hold” rating to a “buy” rating and set a $7.25 price target on the stock in a research note on Thursday, May 12th. Canaccord Genuity set a $4.00 price target on shares of Zafgen and gave the stock a “hold” rating in a research note on Thursday, July 21st. Leerink Swann reaffirmed a “market perform” rating and set a $6.00 price target on shares of Zafgen in a research note on Wednesday, July 20th. Finally, Cowen and Company cut shares of Zafgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 20th. Six analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Zafgen presently has a consensus rating of “Hold” and a consensus price target of $9.22.
The stock has a 50 day moving average of $4.32 and a 200-day moving average of $5.97. The company’s market cap is $84.45 million.
In other news, Director Frances K. Heller acquired 10,000 shares of the business’s stock in a transaction dated Friday, July 22nd. The stock was acquired at an average price of $2.99 per share, for a total transaction of $29,900.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $29,900. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Patricia L. Allen acquired 16,000 shares of the business’s stock in a transaction dated Tuesday, July 26th. The stock was purchased at an average price of $3.12 per share, with a total value of $49,920.00. The disclosure for this purchase can be found here.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.